Inhibidores de ALK: progresos terapéuticos - page 9

ASCEND-5: PFS for ceritinib vs chemotherapy
Scagliotti, et al. ESMO 2016
1.6
5.4
HR=0.49
(95% CI 0.36–0.67)
p<0.001
Ceritinib (n=115)
Chemotherapy (n=116)
1.0
0.8
0.6
0.4
0.2
0
0
PFS estimate
24
12
6
18
Time (months)
INDICACIÓN PENDIENTE DE APROBACIÓN,
1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...48
Powered by FlippingBook